After dosing at 4.5 and 6 mg, mean fasting glucagon levels were decreased from 24 h post-dose up to day 15
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities
Liver fat, visceral fat, lipids, ketones, and insulin are real and measured, but no retatrutide trial has tested insulin sensitivity or longevity as an endpoint
Several notable studies have examined chromium picolinate supplementation at higher doses between 600-1000mcg daily, finding it may influence hunger and food cravings
The medication has also been associated with improvements in various cardiometabolic parameters, including blood pressure, glycemic control, and lipid profiles
Een cross-sectionele studie uit 2025 liet zien dat heel wat gebruikers van GLP-1-receptoragonisten hun eiwitdoel niet halen